Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

Los Angeles, California, UNITED STATES

LOS ANGELES, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with an initial focus on developing the first FDA approved treatment for lactose intolerance, today reported financial results and a business update for the third quarter ended September 30, 2017.

Recent Highlights

  • Announced Phase 3 plans after its End-of-Phase 2 Meeting with the FDA regarding the path forward toward a New Drug Application submission for RP-G28 for the treatment of lactose intolerance
  • Raised approximately $23 million in an underwritten public offering, before deducting underwriting discounts, commissions and other offering expenses, to fund the initiation of its Phase 3 clinical program of RP-G28
  • Initiating the first of two Phase 3 clinical trials in the first half of 2018

“We are very much committed and focused on the clinical development of RP-G28 to NDA submission,” said Michael D. Step, Chief Executive Officer of Ritter Pharmaceuticals. “I’m proud of our clinical and regulatory team’s swift and diligent effort to get us Phase 3 ready and we look forward to initiating our first phase 3 trial in the first half of 2018.”

Andrew J. Ritter, President of Ritter Pharmaceuticals, added, “With Phase 3 guidance from the FDA from our End of Phase 2 Meeting and our recent successful capital raise behind us, we have a clear regulatory pathway and we have sufficient funding to execute the first pivotal Phase 3 clinical trial of RP-G28 through data readout.”

Third Quarter 2017 Financial Results

For the third quarter of 2017, Ritter Pharmaceuticals reported a net loss attributable to common stockholders of approximately $2.0 million compared to a net loss of approximately $3.5 million for the third quarter of 2016. Basic and diluted net loss per share was $0.14 for the three months ended September 30, 2017 compared to basic and diluted net loss per share of $0.41 for the same period in 2016.

Research and development expenses totaled approximately $0.9 million for the quarter ended September 30, 2017 versus $2.3 million for the comparable quarter ended September 30, 2016. The quarter over quarter decrease of approximately $1.4 million was primarily driven by a decrease in activity related to our Phase 2b/3 clinical trial which was initiated in March 2016 and completed in the fourth quarter of 2016. Research and development costs incurred in the quarter ended September 30, 2017 were primarily attributable to Phase 2b/3 extension study fees and Phase 3 program planning expenses.

General and administrative expenses were approximately $1.1 million for both the third quarter of 2017 and 2016.

Total operating expenses for the third quarter of 2017 were approximately $2.0 million compared to approximately $3.5 million for the third quarter of 2016. The decrease of approximately $1.5 million is primarily attributable to the decrease in research and development costs as described above.

As of September 30, 2017, Ritter Pharmaceuticals had cash and cash equivalents of approximately $3.6 million. In addition, the company raised approximately $21.0 million, net of fees, through an underwritten public offering that closed on October 3, 2017.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. (www.RitterPharma.com, @RitterPharma) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The Company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic, and liver disease.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing of our two Phase 3 clinical trials. Management believes that these forward-looking statements are reasonable as and when made.  However, such statements involve a number of known and unknown risks and uncertainties that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of certain risks and uncertainties affecting Ritter Pharmaceuticals’ forward-looking statements, please review the Company’s reports filed with the Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2016 and Quarterly Reports on Form 10-Q for the periods ended March 31, 2017, June 30, 2017 and September 30, 2017. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management’s current expectations and Ritter Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.

Jeffrey Benjamin

  Three Months Ended
September 30,
  Nine Months Ended
September 30,
  2017  2016  2017  2016 
Operating costs and expenses:                
Research and development $915,268  $2,348,755  $2,121,898  $7,112,177 
Patent costs  47,431   98,908   175,794   199,888 
General and administrative  1,052,236   1,091,647   3,367,781   3,533,608 
Total operating costs and expenses  2,014,935   3,539,310   5,665,473   10,845,673 
Operating loss  (2,014,935)  (3,539,310)  (5,665,473)  (10,845,673)
Other income:                
Interest income  4,083   13,239   18,362   50,466 
Other income           1,214 
Total other income  4,083   13,239   18,362   51,680 
Net loss $(2,010,852) $(3,526,071) $(5,647,111) $(10,793,993)
Net loss per common share ― basic and diluted $(0.14) $(0.41) $(0.42) $(1.26)
Weighted-average common shares outstanding — basic and diluted  14,756,521   8,585,406   13,443,007   8,584,442 

  September 30, 2017  December 31, 2016 
Current assets        
Cash and cash equivalents $3,558,874  $7,046,282 
Prepaid expenses  260,597   156,752 
Total current assets  3,819,471   7,203,034 
Other assets  10,326   10,326 
Deferred offering costs  310,786    
Property and equipment, net  19,606   23,542 
Total Assets $4,160,189  $7,236,902 
Current liabilities        
Accounts payable $2,745,370  $1,896,368 
Accrued expenses  196,578   1,222,735 
Other liabilities  15,927   14,736 
Total current liabilities  2,957,875   3,133,839 
Stockholders’ equity        
Preferred stock, $0.001 par value; 15,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2017 and December 31, 2016      
Common stock, $0.001 par value; 225,000,000 shares authorized; 14,756,521 and 11,619,197 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively  14,757   11,619 
Additional paid-in capital  52,302,244   49,559,020 
Accumulated deficit  (51,114,687)  (45,467,576)
Total stockholders’ equity  1,202,314   4,103,063 
Total Liabilities and Stockholders’ Equity $4,160,189  $7,236,902